Skip to main content
Top
Published in: International Urology and Nephrology 1/2010

01-03-2010 | Urology - Original Paper

Up-regulation of microRNA in bladder tumor tissue is not common

Authors: Gang Wang, Honghe Zhang, Huadong He, Wenjuan Tong, Bin Wang, Guodong Liao, Zhaodian Chen, Caigan Du

Published in: International Urology and Nephrology | Issue 1/2010

Login to get access

Abstract

MicroRNAs (miRNAs) have recently been shown to down-regulate gene expression by targeting mRNA translation and to play a critical role in tumorigenesis; how they regulate bladder tumor development, particularly in patients, is, however, poorly understood. The difference in miRNA expression in a bladder tumor compared with healthy tissue from the same patients was examined using microRNA arrays in seven patients. Here, we showed that up-regulation of miRNA was not commonly found in this limited number of patients, and four miRNAs (miR-26a, miR-29c, miR-30c, miR-30e-5p) were down-regulated as a common marker in patients with a 1–3 grade of disease. Our data suggest that instead of up-regulation of carcinogenic miRNAs, loss of regulation of these miRNA may be critical for bladder tumor development in patients.
Literature
1.
go back to reference Yang L, Parkin DM, Li LD, Chen YD, Bray F (2004) Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer 90:2157–2166PubMed Yang L, Parkin DM, Li LD, Chen YD, Bray F (2004) Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer 90:2157–2166PubMed
3.
go back to reference Sobin L, Wittekind C (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley–Liss, New York Sobin L, Wittekind C (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley–Liss, New York
8.
go back to reference Good L (2003) Translation repression by antisense sequences. Cell Mol Life Sci 60:854–861PubMed Good L (2003) Translation repression by antisense sequences. Cell Mol Life Sci 60:854–861PubMed
20.
go back to reference Akao Y, Nakagawa Y, Naoe T (2006) MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16:845–850PubMed Akao Y, Nakagawa Y, Naoe T (2006) MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16:845–850PubMed
21.
22.
go back to reference Sengupta S, den Boon JA, Chen IH et al (2008) MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105:5874–5878. doi:10.1073/pnas.0801130105 CrossRefPubMed Sengupta S, den Boon JA, Chen IH et al (2008) MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105:5874–5878. doi:10.​1073/​pnas.​0801130105 CrossRefPubMed
32.
Metadata
Title
Up-regulation of microRNA in bladder tumor tissue is not common
Authors
Gang Wang
Honghe Zhang
Huadong He
Wenjuan Tong
Bin Wang
Guodong Liao
Zhaodian Chen
Caigan Du
Publication date
01-03-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9584-3

Other articles of this Issue 1/2010

International Urology and Nephrology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.